Description: Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty chemicals in India, Mexico, Spain, Hungary, and internationally. It operates through two segments, Specialty Chemicals Business and Pharma Business. The company is involved in the provision of APIs and intermediates for various generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. The company's products are used in home care, personal care, and industrial product categories. Vivimed Labs Limited was incorporated in 1988 and is headquartered in Hyderabad, India.
Home Page: www.vivimedlabs.com
Officers
| Name | Title |
|---|---|
| Mr. Yugandhar Kopparthi | Compliance Officer & Company Sec. |
| Mr. Santosh Varalwar | MD & Exec. Director |
| Dr. Manohar Rao Varalwar | Whole Time Director |
| Mr. Sandeep Varalwar | Exec. Director |
| Mr. Ramesh Krishnamurthy | Chief Exec. Officer |
Exchange: BSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3288 |
| Price-to-Sales TTM: | 0.4964 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |